_id
69130b06ccc777a4e85d7c5d
Ticker
KNTPF
Name
Kintor Pharmaceutical Limited
Exchange
PINK
Address
Suzhou Industrial Park, Suzhou, China, 215123
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.kintor.com.cn
Description
Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology in the People's Republic of China. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia (AGA) and acne vulgaris, which is in phase III clinical trial; and GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris that is in phase II clinical trial. The company is developing GT1708F (Hedgehog/SMO Inhibitor), an inhibitor of the hedgehog signal transduction pathway to treat idiopathic pulmonary fibrosis, and blood cancer; GT0486, an inhibitor of the PI3K/mTOR signalling pathway and a second generation mTOR inhibitor for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and hepatocellular carcinoma (HCC); and ALK-1 Antibody (GT90001), an anti-angiogenesis inhibitor and targets a new biological target activin receptor-like kinase-1 globally to treat metastatic hepatocellular carcinoma, a common type of liver cancer, and a variety of solid tumours. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China.
Last Close
0.216
Volume
-
Current Price
0.2779
Change
0
Last Updated
2026-01-04T16:07:29.112Z
Image
data:image/webp;base64,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
Ipo Date
-
Market Cap
101283256
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-06-30
Revenue
818570
Cost Of Revenue
2576908
Gross Profit
-1758338
Operating Expenses
9502197
Operating Income
-11260536
Interest Expense
305869
Pretax Income
-11428381
Net Income
-11390489
Eps
-0.026241073464940066
Dividends Per Share
-
Shares Outstanding
468903920
Income Tax Expense
-37891
EBITDA
-9325187
Operating Margin
-1375.6350709163542
Total Other Income Expense Net
-167845
Cash
52862000
Short Term Investments
-
Receivables
7059000
Inventories
2998000
Total Current Assets
63350000
Property Plant Equipment
168353000
Total Assets
391895000
Payables
47082000
Short Term Debt
87397000
Long Term Debt
0
Total Liabilities
175890000
Equity
216005000
Bs_currency_symbol
CNY
Depreciation
12658000
Change In Working Capital
-
Cash From Operations
-9509994
Capital Expenditures
900000
Cash From Investing
2015236
Cash From Financing
-5479522
Net Change In Cash
-12811801
Cf_currency_symbol
-
PE
-
PB
0.5584515677877827
ROE
-5.273252471007615
ROA
-2.9065155207389735
FCF
-10409994
Fcf Percent
-12.717292351295551
Piotroski FScore
1
Health Score
30
Deep Value Investing Score
6
Defensive Investing Score
5.5
Dividend Investing Score
1.5
Economic Moat Investing Score
4.8
Garp Investing Score
2
Growth Investing Score
1
Momentum Investing Score
4
Net Net Investing Score
2
Quality Investing Score
2.5
Value Investing Score
5
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
818570
Quarters > 0 > income Statement > cost Of Revenue
2576908
Quarters > 0 > income Statement > gross Profit
-1758338
Quarters > 0 > income Statement > operating Expenses
9502197
Quarters > 0 > income Statement > operating Income
-11260536
Quarters > 0 > income Statement > interest Expense
305869
Quarters > 0 > income Statement > pretax Income
-11428381
Quarters > 0 > income Statement > net Income
-11390489
Quarters > 0 > income Statement > eps
-0.026241073464940066
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
434071000
Quarters > 0 > income Statement > income Tax Expense
-37891
Quarters > 0 > income Statement > EBITDA
-9325187
Quarters > 0 > income Statement > operating Margin
-1375.6350709163542
Quarters > 0 > income Statement > total Other Income Expense Net
-167845
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
52862000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
7059000
Quarters > 0 > balance Sheet > inventories
2998000
Quarters > 0 > balance Sheet > total Current Assets
63350000
Quarters > 0 > balance Sheet > property Plant Equipment
168353000
Quarters > 0 > balance Sheet > total Assets
391895000
Quarters > 0 > balance Sheet > payables
47082000
Quarters > 0 > balance Sheet > short Term Debt
87397000
Quarters > 0 > balance Sheet > long Term Debt
0
Quarters > 0 > balance Sheet > total Liabilities
175890000
Quarters > 0 > balance Sheet > equity
216005000
Quarters > 0 > balance Sheet > currency_symbol
CNY
Quarters > 0 > cash Flow > net Income
-83268000
Quarters > 0 > cash Flow > depreciation
12658000
Quarters > 0 > cash Flow > change In Working Capital
-
Quarters > 0 > cash Flow > cash From Operations
-9509994
Quarters > 0 > cash Flow > capital Expenditures
900000
Quarters > 0 > cash Flow > cash From Investing
2015236
Quarters > 0 > cash Flow > cash From Financing
-5479522
Quarters > 0 > cash Flow > net Change In Cash
-12811801
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-0.026241073464940066
Quarters > 0 > ratios > PB
0.5584515677877827
Quarters > 0 > ratios > ROE
-5.273252471007615
Quarters > 0 > ratios > ROA
-2.9065155207389735
Quarters > 0 > ratios > FCF
-10409994
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-12.717292351295551
Quarters > 0 > health Score
30
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
2500000
Quarters > 1 > income Statement > cost Of Revenue
4865000
Quarters > 1 > income Statement > gross Profit
-2365000
Quarters > 1 > income Statement > operating Expenses
69919000
Quarters > 1 > income Statement > operating Income
-72284000
Quarters > 1 > income Statement > interest Expense
4638500
Quarters > 1 > income Statement > pretax Income
-77637000
Quarters > 1 > income Statement > net Income
-77646000
Quarters > 1 > income Statement > eps
-0.18026857105710387
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
430724000
Quarters > 1 > income Statement > income Tax Expense
9000
Quarters > 1 > income Statement > EBITDA
-64185000
Quarters > 1 > income Statement > operating Margin
-2891.3599999999997
Quarters > 1 > income Statement > total Other Income Expense Net
-5353000
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
147419000
Quarters > 1 > balance Sheet > short Term Investments
1270000
Quarters > 1 > balance Sheet > receivables
2142607
Quarters > 1 > balance Sheet > inventories
2215000
Quarters > 1 > balance Sheet > total Current Assets
171730000
Quarters > 1 > balance Sheet > property Plant Equipment
165899000
Quarters > 1 > balance Sheet > total Assets
515126000
Quarters > 1 > balance Sheet > payables
39373000
Quarters > 1 > balance Sheet > short Term Debt
113009000
Quarters > 1 > balance Sheet > long Term Debt
20000000
Quarters > 1 > balance Sheet > total Liabilities
221046000
Quarters > 1 > balance Sheet > equity
294080000
Quarters > 1 > balance Sheet > currency_symbol
CNY
Quarters > 1 > cash Flow > net Income
-83799000
Quarters > 1 > cash Flow > depreciation
8887000
Quarters > 1 > cash Flow > change In Working Capital
-1182000
Quarters > 1 > cash Flow > cash From Operations
-12213102
Quarters > 1 > cash Flow > capital Expenditures
1046000
Quarters > 1 > cash Flow > cash From Investing
2744867
Quarters > 1 > cash Flow > cash From Financing
-14630307
Quarters > 1 > cash Flow > net Change In Cash
-24199268
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
-0.18026857105710387
Quarters > 1 > ratios > PB
0.40702597796517953
Quarters > 1 > ratios > ROE
-26.40301958650707
Quarters > 1 > ratios > ROA
-15.073205390525812
Quarters > 1 > ratios > FCF
-13259102
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-5.3036408
Quarters > 1 > health Score
30
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
2500000
Quarters > 2 > income Statement > cost Of Revenue
4865000
Quarters > 2 > income Statement > gross Profit
-2365000
Quarters > 2 > income Statement > operating Expenses
69919000
Quarters > 2 > income Statement > operating Income
-72284000
Quarters > 2 > income Statement > interest Expense
4638500
Quarters > 2 > income Statement > pretax Income
-77637000
Quarters > 2 > income Statement > net Income
-77646000
Quarters > 2 > income Statement > eps
-0.18026857105710387
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
430724000
Quarters > 2 > income Statement > income Tax Expense
9000
Quarters > 2 > income Statement > EBITDA
-64185000
Quarters > 2 > income Statement > operating Margin
-2891.3599999999997
Quarters > 2 > income Statement > total Other Income Expense Net
-5353000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
322656000
Quarters > 2 > balance Sheet > short Term Investments
11110000
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
200000
Quarters > 2 > balance Sheet > total Current Assets
371350000
Quarters > 2 > balance Sheet > property Plant Equipment
191407000
Quarters > 2 > balance Sheet > total Assets
739541000
Quarters > 2 > balance Sheet > payables
46994000
Quarters > 2 > balance Sheet > short Term Debt
178891000
Quarters > 2 > balance Sheet > long Term Debt
59200000
Quarters > 2 > balance Sheet > total Liabilities
347966000
Quarters > 2 > balance Sheet > equity
391575000
Quarters > 2 > balance Sheet > currency_symbol
CNY
Quarters > 2 > cash Flow > net Income
-71493000
Quarters > 2 > cash Flow > depreciation
8740000
Quarters > 2 > cash Flow > change In Working Capital
-
Quarters > 2 > cash Flow > cash From Operations
-15352704
Quarters > 2 > cash Flow > capital Expenditures
492000
Quarters > 2 > cash Flow > cash From Investing
-94340
Quarters > 2 > cash Flow > cash From Financing
-2064535
Quarters > 2 > cash Flow > net Change In Cash
-18411948
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
-0.18026857105710387
Quarters > 2 > ratios > PB
0.3056839675668773
Quarters > 2 > ratios > ROE
-19.829151503543383
Quarters > 2 > ratios > ROA
-10.499215053661663
Quarters > 2 > ratios > FCF
-15844704
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-6.3378816
Quarters > 2 > health Score
30
Quarters > 3 > quarter
2024-03-31
Quarters > 3 > income Statement > revenue
156.22
Quarters > 3 > income Statement > cost Of Revenue
78.11
Quarters > 3 > income Statement > gross Profit
78.11
Quarters > 3 > income Statement > operating Expenses
4510.21
Quarters > 3 > income Statement > operating Income
-4588.32
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-4949.45
Quarters > 3 > income Statement > net Income
-4950.7
Quarters > 3 > income Statement > eps
-0.000011501887669164197
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
430425000
Quarters > 3 > income Statement > income Tax Expense
1.25
Quarters > 3 > income Statement > EBITDA
-4505366.66
Quarters > 3 > income Statement > operating Margin
-2937.0887210344385
Quarters > 3 > income Statement > total Other Income Expense Net
-361124.58
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
322656000
Quarters > 3 > balance Sheet > short Term Investments
11010000
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
200000
Quarters > 3 > balance Sheet > total Current Assets
371350000
Quarters > 3 > balance Sheet > property Plant Equipment
191407000
Quarters > 3 > balance Sheet > total Assets
739541000
Quarters > 3 > balance Sheet > payables
51048000
Quarters > 3 > balance Sheet > short Term Debt
178891000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
347966000
Quarters > 3 > balance Sheet > equity
391575000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-35746500
Quarters > 3 > cash Flow > depreciation
4370000
Quarters > 3 > cash Flow > change In Working Capital
-
Quarters > 3 > cash Flow > cash From Operations
-55330500
Quarters > 3 > cash Flow > capital Expenditures
246000
Quarters > 3 > cash Flow > cash From Investing
-340000
Quarters > 3 > cash Flow > cash From Financing
-7440500
Quarters > 3 > cash Flow > net Change In Cash
-8645.25
Quarters > 3 > cash Flow > currency_symbol
-
Quarters > 3 > ratios > PE
-0.000011501887669164197
Quarters > 3 > ratios > PB
0.30547176786056307
Quarters > 3 > ratios > ROE
-0.0012643044116708165
Quarters > 3 > ratios > ROA
-0.0006694287402591607
Quarters > 3 > ratios > FCF
-55576500
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-355757.90551785944
Quarters > 3 > health Score
29
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
5000000
Annuals > 0 > income Statement > cost Of Revenue
9730000
Annuals > 0 > income Statement > gross Profit
-4730000
Annuals > 0 > income Statement > operating Expenses
139838000
Annuals > 0 > income Statement > operating Income
-144568000
Annuals > 0 > income Statement > interest Expense
9277000
Annuals > 0 > income Statement > pretax Income
-155274000
Annuals > 0 > income Statement > net Income
-155292000
Annuals > 0 > income Statement > eps
-0.36053714211420773
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
430724000
Annuals > 0 > income Statement > income Tax Expense
18000
Annuals > 0 > income Statement > EBITDA
-128370000
Annuals > 0 > income Statement > operating Margin
-2891.3599999999997
Annuals > 0 > income Statement > total Other Income Expense Net
-10706000
Annuals > 0 > income Statement > currency_symbol
CNY
Annuals > 0 > balance Sheet > cash
147419000
Annuals > 0 > balance Sheet > short Term Investments
1270000
Annuals > 0 > balance Sheet > receivables
2142607
Annuals > 0 > balance Sheet > inventories
2215000
Annuals > 0 > balance Sheet > total Current Assets
171730000
Annuals > 0 > balance Sheet > property Plant Equipment
165899000
Annuals > 0 > balance Sheet > total Assets
515126000
Annuals > 0 > balance Sheet > payables
39373000
Annuals > 0 > balance Sheet > short Term Debt
113009000
Annuals > 0 > balance Sheet > long Term Debt
20000000
Annuals > 0 > balance Sheet > total Liabilities
221046000
Annuals > 0 > balance Sheet > equity
294080000
Annuals > 0 > balance Sheet > currency_symbol
CNY
Annuals > 0 > cash Flow > net Income
-155274000
Annuals > 0 > cash Flow > depreciation
17627000
Annuals > 0 > cash Flow > change In Working Capital
-51136000
Annuals > 0 > cash Flow > cash From Operations
-199080000
Annuals > 0 > cash Flow > capital Expenditures
1680000
Annuals > 0 > cash Flow > cash From Investing
20034000
Annuals > 0 > cash Flow > cash From Financing
-119671000
Annuals > 0 > cash Flow > net Change In Cash
-296608000
Annuals > 0 > cash Flow > currency_symbol
CNY
Annuals > 0 > ratios > PE
-0.36053714211420773
Annuals > 0 > ratios > PB
0.31636420021762784
Annuals > 0 > ratios > ROE
-52.80603917301414
Annuals > 0 > ratios > ROA
-30.146410781051625
Annuals > 0 > ratios > FCF
-200760000
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-40.152
Annuals > 0 > health Score
30
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
42229000
Annuals > 1 > income Statement > gross Profit
-42229000
Annuals > 1 > income Statement > operating Expenses
1016994000
Annuals > 1 > income Statement > operating Income
-152389649
Annuals > 1 > income Statement > interest Expense
9690000
Annuals > 1 > income Statement > pretax Income
-151214858
Annuals > 1 > income Statement > net Income
-1060820000
Annuals > 1 > income Statement > eps
-2.4723762378545175
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
429069000
Annuals > 1 > income Statement > income Tax Expense
-8041000
Annuals > 1 > income Statement > EBITDA
-1055821000
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
1174790
Annuals > 1 > income Statement > currency_symbol
CNY
Annuals > 1 > balance Sheet > cash
445499000
Annuals > 1 > balance Sheet > short Term Investments
10000000
Annuals > 1 > balance Sheet > receivables
9496000
Annuals > 1 > balance Sheet > inventories
-9496000
Annuals > 1 > balance Sheet > total Current Assets
472557000
Annuals > 1 > balance Sheet > property Plant Equipment
190713000
Annuals > 1 > balance Sheet > total Assets
869232000
Annuals > 1 > balance Sheet > payables
68288000
Annuals > 1 > balance Sheet > short Term Debt
118230000
Annuals > 1 > balance Sheet > long Term Debt
133400000
Annuals > 1 > balance Sheet > total Liabilities
411120000
Annuals > 1 > balance Sheet > equity
458112000
Annuals > 1 > balance Sheet > currency_symbol
CNY
Annuals > 1 > cash Flow > net Income
-1068861000
Annuals > 1 > cash Flow > depreciation
18976000
Annuals > 1 > cash Flow > change In Working Capital
-96481000
Annuals > 1 > cash Flow > cash From Operations
-387581000
Annuals > 1 > cash Flow > capital Expenditures
2723000
Annuals > 1 > cash Flow > cash From Investing
3274000
Annuals > 1 > cash Flow > cash From Financing
-33463000
Annuals > 1 > cash Flow > net Change In Cash
-420443000
Annuals > 1 > cash Flow > currency_symbol
CNY
Annuals > 1 > ratios > PE
-2.4723762378545175
Annuals > 1 > ratios > PB
0.2023062133277452
Annuals > 1 > ratios > ROE
-231.56346046381674
Annuals > 1 > ratios > ROA
-122.04106613654353
Annuals > 1 > ratios > FCF
-390304000
Annuals > 1 > ratios > Piotroski FScore
1
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
30
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
2737238
Annuals > 2 > income Statement > gross Profit
-2737238
Annuals > 2 > income Statement > operating Expenses
143227323
Annuals > 2 > income Statement > operating Income
-944529000
Annuals > 2 > income Statement > interest Expense
8187000
Annuals > 2 > income Statement > pretax Income
-953284000
Annuals > 2 > income Statement > net Income
-954369000
Annuals > 2 > income Statement > eps
-2.5344003441627763
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
376566000
Annuals > 2 > income Statement > income Tax Expense
1085000
Annuals > 2 > income Statement > EBITDA
-956446000
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
-8755000
Annuals > 2 > income Statement > currency_symbol
CNY
Annuals > 2 > balance Sheet > cash
865081
Annuals > 2 > balance Sheet > short Term Investments
11875
Annuals > 2 > balance Sheet > receivables
874204044
Annuals > 2 > balance Sheet > inventories
603503000
Annuals > 2 > balance Sheet > total Current Assets
1507869000
Annuals > 2 > balance Sheet > property Plant Equipment
282477000
Annuals > 2 > balance Sheet > total Assets
2055136000
Annuals > 2 > balance Sheet > payables
78453000
Annuals > 2 > balance Sheet > short Term Debt
103335000
Annuals > 2 > balance Sheet > long Term Debt
177600000
Annuals > 2 > balance Sheet > total Liabilities
559948000
Annuals > 2 > balance Sheet > equity
1495188000
Annuals > 2 > balance Sheet > currency_symbol
CNY
Annuals > 2 > cash Flow > net Income
-954369
Annuals > 2 > cash Flow > depreciation
18237
Annuals > 2 > cash Flow > change In Working Capital
-197952000
Annuals > 2 > cash Flow > cash From Operations
-961260
Annuals > 2 > cash Flow > capital Expenditures
27470
Annuals > 2 > cash Flow > cash From Investing
67195
Annuals > 2 > cash Flow > cash From Financing
815750
Annuals > 2 > cash Flow > net Change In Cash
-61861
Annuals > 2 > cash Flow > currency_symbol
CNY
Annuals > 2 > ratios > PE
-2.5344003441627763
Annuals > 2 > ratios > PB
0.054400019261791825
Annuals > 2 > ratios > ROE
-63.82936460164207
Annuals > 2 > ratios > ROA
-46.43824058359155
Annuals > 2 > ratios > FCF
-988730
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
34
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
34231000
Annuals > 3 > income Statement > cost Of Revenue
0
Annuals > 3 > income Statement > gross Profit
34231000
Annuals > 3 > income Statement > operating Expenses
873832000
Annuals > 3 > income Statement > operating Income
-839601000
Annuals > 3 > income Statement > interest Expense
2494000
Annuals > 3 > income Statement > pretax Income
-842095000
Annuals > 3 > income Statement > net Income
-842095000
Annuals > 3 > income Statement > eps
-2362.8269915514616
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
356393
Annuals > 3 > income Statement > income Tax Expense
-229829
Annuals > 3 > income Statement > EBITDA
-827967000
Annuals > 3 > income Statement > operating Margin
-2452.7504308959715
Annuals > 3 > income Statement > total Other Income Expense Net
-2494000
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
930149
Annuals > 3 > balance Sheet > short Term Investments
126580
Annuals > 3 > balance Sheet > receivables
1054163271
Annuals > 3 > balance Sheet > inventories
351362000
Annuals > 3 > balance Sheet > total Current Assets
1525895
Annuals > 3 > balance Sheet > property Plant Equipment
262300
Annuals > 3 > balance Sheet > total Assets
2067989000
Annuals > 3 > balance Sheet > payables
44700000
Annuals > 3 > balance Sheet > short Term Debt
9469000
Annuals > 3 > balance Sheet > long Term Debt
147500000
Annuals > 3 > balance Sheet > total Liabilities
412831000
Annuals > 3 > balance Sheet > equity
1655158000
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-516274
Annuals > 3 > cash Flow > depreciation
10367
Annuals > 3 > cash Flow > change In Working Capital
-284588000
Annuals > 3 > cash Flow > cash From Operations
-1051363
Annuals > 3 > cash Flow > capital Expenditures
76238
Annuals > 3 > cash Flow > cash From Investing
92005
Annuals > 3 > cash Flow > cash From Financing
857418
Annuals > 3 > cash Flow > net Change In Cash
-138358
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-2362.8269915514616
Annuals > 3 > ratios > PB
0.00004650969152189701
Annuals > 3 > ratios > ROE
-50.87701597068075
Annuals > 3 > ratios > ROA
-40.72047772014261
Annuals > 3 > ratios > FCF
-1127601
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-0.03294093073529841
Annuals > 3 > health Score
33
Valuation > metrics > PE
-0.026241073464940066
Valuation > metrics > PB
0.5584515677877827
Valuation > final Score
70
Valuation > verdict
44.2% Undervalued
Profitability > metrics > ROE
-5.273252471007615
Profitability > metrics > ROA
-17.980250986582476
Profitability > metrics > Net Margin
-13.915106832647178
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.8142867063262424
Risk > metrics > Interest Coverage
-36.814897881119045
Risk > final Score
-99
Risk > verdict
High
Liquidity > metrics > Current Ratio
0.47107726856981386
Liquidity > metrics > Quick Ratio
0.44878382498382646
Liquidity > final Score
32
Liquidity > verdict
Weak
Prev Valuations > 0
70
Prev Valuations > 1
70
Prev Valuations > 2
70
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
-14
Prev Risks > 1
-14
Prev Risks > 2
48
Prev Liquidities > 0
78
Prev Liquidities > 1
91
Prev Liquidities > 2
90
Updated At
2026-01-20T22:06:25.188Z
Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology in the People's Republic of China. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia (AGA) and acne vulgaris, which is in phase III clinical trial; and GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris that is in phase II clinical trial. The company is developing GT1708F (Hedgehog/SMO Inhibitor), an inhibitor of the hedgehog signal transduction pathway to treat idiopathic pulmonary fibrosis, and blood cancer; GT0486, an inhibitor of the PI3K/mTOR signalling pathway and a second generation mTOR inhibitor for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and hepatocellular carcinoma (HCC); and ALK-1 Antibody (GT90001), an anti-angiogenesis inhibitor and targets a new biological target activin receptor-like kinase-1 globally to treat metastatic hepatocellular carcinoma, a common type of liver cancer, and a variety of solid tumours. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AKintor Shares Plunge After Hair-Loss Drug Flops In Clinical Trials Seeking Alpha
Read more →(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Kintor Pharmaceutical Limited
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-06-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.